Hypophosphatemic rickets linked to the X (XLH) chromosome – 
KRN 23 (burosumab) therapy: expert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association 
of J.E. Purkyně

Burnett CH, Dent CE, Harper C et al. Vitamin D-Resistant Rickets. Analysis of Twenty-Four Pedigrees with Hereditary and Sporadic Cases. Am J Med 1964; 36: 222–232.

Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 2005; 16(9): 2565–2575.

Beck-Nielsen SS, Brock-Jacobsen B, Gram Jet al. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 2009; 160(3): 491–497.

Rafaelsen SH, Johansson S, Raeder H et al. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes and treatment complications. Eur J Endocrinol 2015; 174(2): 125–136.

Endo I, Fukumoto S, Ozono K et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 2015; 62(9):811–816.

Carpenter TO. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin North Am 1997; 44(2): 443–466.

de Paula FJ, Rosen CJ. Bone Remodeling and Energy Metabolism: New Perspectives. Bone Res 2013; 1(1): 72–84.

Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977; 137(2): 203–220.

Glorieux FH, Marie PJ, Pettifor JM et al. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 1980; 303(18): 1023–1031.

Imel EA, DiMeglio LA, Hui SLet al. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010; 95(4): 1846–1850.

Carpenter TO, Imel EA, Holm IA et al. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26(7): 1381–1388.

Beck-Nielsen H. The metabolic syndrome in the daily clinic. Ugeskr Laeger 2010; 172(23): 1746–1751.

Berndt M, Ehrich JH, Lazovic D et al. Clinical course of hypophosphatemic rickets in 23 adults. Clin Nephrol 1996; 45(1): 33–41.

Hardy DC, Murphy WA, Siegel BA et al. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology 1989; 171(2): 403–414.

Reid IR, Hardy DC, Murphy WA et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore) 1989; 68(6): 336–352.

Whyte M et al. Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody for X-linked Hypophosphatemia (XLH): Final 64-Week Results of a Randomized, Open-label Phase 2. Study of 52 Children. Oral presentation 1154. The Annual American Society for Bone and Mineral Research Meeting 2017; Denver, CO, USA.

Carpenter TO et al. Effects of Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody, on Functional Outcomes in Children with X-linked Hypophosphatemia (XLH): Final Results from a Randomized, 64-week, Open-label Phase 2 Study Oral presentation 331. The Annual American Society for Bone and Mineral Research Meeting 2017; Denver, CO, USA.

Imel EA et al. Oral presentation at the ICCBH 2017; Würzburg, Germany.

Imel EA et al. The Effects of Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody, on Phosphate Metabolism and Rickets in 1 to 4-Year-Old Children with X-linked Hypophosphatemia (XLH). Oral presentation 695. The Annual American Society for Bone and Mineral Research Meeting 2017; Denver, CO, USA.

Makitie O, Doria A, Kooh SW et al. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003; 88(8): 3591–3597.

Quinlan C, Guegan K, Offiah A et al. Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 2012; 27(4): 581–588.

Informace dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT02526160>.

Informace dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT02163577>.

24. Barth JH, Jones RG, Payne RB. Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomo_{gram. Ann Clin Biochem 2000; 37(Pt 1): 79–81.}